For research and educational purposes only. Not medical advice.
GHRH 1-44 Reference
Educational, not medical advice reference for GHRH 1-44: GH Release; regulatory status, evidence posture, source review, and schedule notes. Als…
Reference summary
Older human GH-provocative-test literature exists for GHRH 1-44. Modern outcome programs are limited; current community use extrapolates from the broader GHRH-analog class.
Regulatory and posture
- Categories
- GH Release
- Aliases
- Growth hormone-releasing hormone (full length), Somatorelin, Somatocrinin
- Evidence posture
- human - Older small human GH-provocative-test studies dominate the literature. No modern PK/PD or outcome program is established for full-length GHRH 1-44 as a research peptide.
- Regulatory status
- No FDA-approved GHRH 1-44 drug label currently on the US market. Sermorelin (GHRH 1-29) was previously FDA-approved as Geref but withdrawn; full-length GHRH 1-44 is not currently approved as a stand-alone product in the United States.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed search: GHRH 1-44 (full-length growth hormone-releasing hormone) human trials
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.